Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
ReCode Therapeutics announced the appointment of Shehnaaz Suliman as CEO and board member, effective immediately. Former CEO David Lockhart transitions to Chief Scientific Officer. Dr. Suliman, with over 25 years in drug development, previously led Alector and held key roles at Theravance and Roche. She aims to advance ReCode's pipeline of genetic medicines utilizing their selective organ targeting platform. The leadership change is anticipated to enhance growth and innovative therapeutics in the biopharmaceutical space.
10x Genomics (Nasdaq: TXG) announced participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. The presentation will be accessible via a live and archived webcast on the company's website. 10x Genomics specializes in life science technology, offering integrated solutions for biological analysis.
Its products are utilized globally, including by top research institutions and pharmaceutical companies. The company boasts over 1,200 patents and has contributed to significant research in areas like oncology and neuroscience.
Summary not available.
10x Genomics (TXG) reported third-quarter 2021 revenue of $125.3 million, marking a 74% increase from the previous year and an 8% rise sequentially. The company launched the Chromium X instrument and increased its installed base, contributing to higher consumables revenue. Operating expenses decreased to $116.7 million, down 5% year-over-year, primarily due to lower R&D expenses. The operating loss improved to $15.9 million from $65.3 million in Q3 2020. Net loss narrowed to $17.2 million compared to $65.8 million a year prior. 2021 revenue guidance was revised to $490-$500 million, indicating 64%-67% growth.
Summary not available.
10x Genomics (Nasdaq: TXG) will report its third quarter 2021 financial results after market close on November 3, 2021. Management will host a conference call at 1:30 p.m. PT to discuss the results and future business outlook. The call will be accessible via a live webcast on the company’s website, which will also archive the event for 45 days.
10x Genomics focuses on life science technology, providing integrated solutions for biological analysis, adopted by leading global research institutions and cited in over 2,800 research papers.
10x Genomics (Nasdaq: TXG) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13th at 2:45 p.m. ET. The presentation will be accessible via a live and archived webcast through the company’s Investors’ section. 10x Genomics is a leader in life science technology, providing innovative solutions for analyzing biological systems. Their products are recognized globally, with over 2,800 research citations and a strong patent portfolio of more than 1,150 patents and applications.
10x Genomics, Inc. (Nasdaq: TXG) has announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit, scheduled for August 10, 2021, at 6:00 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the company’s website in the 'Investors' section. 10x Genomics specializes in life science technology, providing integrated solutions for biological system analysis, with over 1,150 patents and applications. Their products are widely used in top global research institutions and pharmaceutical companies.
10x Genomics, Inc. (TXG) reported Q2 2021 revenues of $115.8 million, marking a 170% increase year-over-year and a 9% increase sequentially. This growth was driven by higher consumables revenue amid decreased pandemic impacts. The company launched Chromium X and began shipping Visium Spatial Gene Expression for FFPE. Gross margin improved to 96% due to a reversal of $14.7 million in accrued royalties linked to a settlement with Bio-Rad. While operating expenses rose to $121.3 million, the operating loss decreased to $10.3 million. Full-year revenue guidance of $480 million to $500 million remains unchanged.
10x Genomics, Inc. (Nasdaq: TXG) announced a global settlement and cross-license agreement with Bio-Rad Laboratories, resolving all ongoing litigation. The agreement provides both companies a non-exclusive, royalty-bearing license for single cell analysis products, excluding spatial and digital PCR products. 10x Genomics has invested nearly $1 billion in R&D, resulting in over 1,100 patents, underscoring the strength of its innovation. The settlement eliminates legal disputes, allowing both companies to focus on product development and market growth.